Abstract
Information on severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spread in Africa is limited by fragile surveillance systems and insufficient diagnostic capacity.
We assessed the coronavirus disease-19 (COVID-19)-related diagnostic workload in Benin, Western Africa, characterized SARS-CoV-2 genomes from 12 acute cases of COVID-19, used those together with public data to estimate SARS-CoV-2 transmission dynamics in a Bayesian framework, validated a widely used diagnostic dual target RT-PCR kit donated to African countries, and conducted serological analyses in 68 sera from confirmed COVID-19 cases and from febrile patients sampled before the predicted SARS-CoV-2 introduction.
We found a 15-fold increase in the monthly laboratory workload due to COVID-19. Genomic surveillance showed introductions of three distinct SARS-CoV-2 lineages. SARS-CoV-2 genome-based analyses yielded an R0 estimate of 4.4 (95% confidence interval: 2.0-7.7), suggesting intense spread of SARS-CoV-2 in Africa. RT-PCR-based tests were highly sensitive but showed variation of internal controls and between diagnostic targets. Commercially available SARS-CoV-2 ELISAs showed up to 25% false-positive results depending on antigen and antibody types, likely due to unspecific antibody responses elicited by acute malaria according to lack of SARS-CoV-2-specific neutralizing antibody responses and relatively higher parasitemia in those sera.
We confirm an overload of the diagnostic capacity in Benin and provide baseline information on the usability of genome-based surveillance in resource-limited settings. Sero-epidemiological studies needed to assess SARS-CoV-2 spread may be put at stake by low specificity of tests in tropical settings globally. The increasing diagnostic challenges demand continuous support of national and supranational African stakeholders.
Funding This work was supported by the Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Deutsche Gesellschaft fuer Internationale Zusammenarbeit (GIZ) GmbH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the ethics committee of the Ministry of Health (Arrete 2020 No. 030/MS/DC/SGM/DNSP/CJ/SA/027SGG2020) and followed the Declaration of Helsinki. Written consent was obtained from all the patients participating in the study. Anonymized datasets were used, and all analysis of personally identifiable data took place only in the LFHB.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The nucleotide sequences of the SARS-CoV-2 genomes used in this study are available at the GISAID database (https://www.gisaid.org/) under accession IDs EPI_ISL_476822- EPI_ISL_476831 and EPI_ISL_476833- EPI_ISL_476834 and have been deposited in GenBank under accession numbers MT653071-MT653082.
